1. DHT-dependent phase of prostate cancer.
DHT-dependent phase of prostate cancer. In this phase of prostate cancer, some tumors rely mainly on DHT. The source of testosterone (T) is mainly from the testis, and adrenal glands provide dehydroepiandrosterone (DHEA). Testosterone and DHEA are converted to DHT by 5-α-reductases (SRD5A) present in the prostate. AR has higher affinity for DHT than testosterone. For this reason, finasteride and dutasteride, which inhibit type I or both type I and type II 5-α-reductase activity, respectively, can suppress tumor development or growth, accounting for suppression of low-grade cancers, but not high-grade cancers, in a proportion of men with prostate cancer.
Christopher J. Logothetis et al. Cancer Discovery 2013;3:
©2013 by American Association for Cancer Research